Risedronic acid (sodium)

Risedronic acid (Risedronate) sodium, a bisphosphonate, is a potent anti-resorption agent that inhibits osteoclast-mediated bone resorption and changes the bone metabolism. Risedronic acid sodium suppresses osteoblast differentiation and induced caspase- and isoprenoid depletion-dependent apoptosis. Risedronic acid sodium inhibits blood stages of Plasmodium falciparum (IC50 of 20.3 μM) . Risedronic acid sodium inhibits the transfer of the farnesyl pyrophosphate group to parasite proteins[1][2][3].

Product Specifications

CAS Number

[115436-72-1]

Product Name Alternative

Risedronate (sodium)

UNSPSC

12352005

Hazard Statement

H302+H312+H332

Target

Apoptosis; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis

Field of Research

Cancer; Infection; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/risedronic-acid-sodium.html

Purity

99.72

Solubility

DMSO : < 1 mg/mL|H2O : 8.33 mg/mL (ultrasonic)

Smiles

OC(P(O)(O[Na])=O)(P(O)(O)=O)CC1=CN=CC=C1

Molecular Formula

C7H10NNaO7P2

Molecular Weight

305.09

Precautions

H302+H312+H332

References & Citations

[1]Fujita H, et al. Effect of risedronate on osteoblast differentiation, expression of receptor activator of NF-κB ligand and apoptosis in mesenchymal stem cells. Basic Clin Pharmacol Toxicol. 2011 Aug;109 (2) :78-84. |[2]Jordao FM, et al. In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob Agents Chemother. 2011 May;55 (5) :2026-31.|[3]Willey JS, et al. Risedronate prevents early radiation-induced osteoporosis in mice at multiple skeletal locations. Bone. 2010 Jan;46 (1) :101-11.